

Certificate of Analysis for NR-55712

Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.621 Lineage (Mu Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells

Catalog No. NR-55712

This reagent is the tangible property of the U.S. Government.

Product Description:


A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), B.1.621 lineage (Mu variant) was produced in human embryonic kidney HEK293 (Freestyle 293F) cells and purified by immobilized metal affinity (Ni-NTA) and gel filtration (Superdex 16-600) chromatography. NR-55712 lacks the signal sequence and contains 1197 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag™ BirA biotinylation acceptor sequence. NR-55712 includes T95I, insert143T, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H and D950N mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). Quality control testing was completed just prior to vialing.

Lot: 70047327 Manufacturing Date: 24SEP2021

| TEST | SPECIFICATIONS | RESULTS |
|---|----------------|---|
| Appearance | Report results | Clear and colorless |
| Purity Analytical Fast Protein Liquid Chromatography (FPLC) | Report results | Peak observed at expected retention time (Figure 1) |
| Protein Concentration (A ₂₈₀) | Report results | 0.25 mg per mL |
| Final Product | | |
| Amount per vial | Report results | 25 μg |
| Volume per vial | Report results | 100 μL |
| Functional Activity by Direct ELISA | | |
| SARS-CoV-2 spike (S309) antibody ¹ | Report results | Reactive (Figure 2) |
| SARS-CoV-2 spike S1 antibody ² | Report results | Reactive (Figure 3) |

¹Pinto, D., et al. "Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody." <u>Nature</u> 583 (2020): 290-295. PubMed: 32422645.

²Using SARS-CoV-2 (2019-nCoV) Spike S1 Antibody, Rabbit mAb (Sino Biological catalog number 40150-R007)



BEI Resources www.beiresources.org E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898



Certificate of Analysis for NR-55712

Figure 2: Direct ELISA with S309 mAb





Figure 3: Direct ELISA with Spike S1 mAb



/Heather Couch/
Heather Couch 29 OCT 2021

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the contractor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898